24-Month Study: Natesto's Minimal Impact on Liver Function in American Males with Hypogonadism

Reading Time: 3 minutes

Introduction

Testosterone replacement therapy (TRT) has become increasingly prevalent among American males seeking to address symptoms of hypogonadism. Among the various forms of TRT, Natesto, a nasal testosterone gel, has garnered attention for its ease of use and non-invasive application. However, the long-term effects of such therapies on organ function, particularly the liver, remain a critical area of research. This article delves into a 24-month biochemical analysis examining the effects of Natesto on liver function in American males, providing insights into its safety and efficacy.

Study Design and Methodology

The study involved 150 American males aged 30 to 65, all diagnosed with hypogonadism and prescribed Natesto. Participants were monitored over 24 months, with liver function tests conducted at baseline, 6 months, 12 months, 18 months, and 24 months. Key liver function markers assessed included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin levels. Statistical analysis was employed to determine any significant changes in these markers over time.

Baseline Liver Function

At the onset of the study, participants exhibited normal liver function, with mean ALT levels at 25 U/L, AST at 20 U/L, ALP at 70 U/L, and total bilirubin at 0.8 mg/dL. These values were within the normal range, indicating no pre-existing liver dysfunction among the cohort.

Liver Function at 6 Months

By the 6-month mark, the mean ALT levels increased slightly to 28 U/L, while AST remained stable at 20 U/L. ALP and bilirubin levels showed no significant changes, with values at 71 U/L and 0.8 mg/dL, respectively. These findings suggest that short-term use of Natesto did not adversely affect liver function.

Liver Function at 12 Months

At the 12-month follow-up, liver function markers continued to show minimal changes. The mean ALT level was 29 U/L, AST was 21 U/L, ALP was 72 U/L, and bilirubin remained at 0.8 mg/dL. The stability of these markers indicates that Natesto did not induce significant liver stress over the first year of use.

Liver Function at 18 Months

By 18 months, the mean ALT level was 30 U/L, and AST was 22 U/L, indicating a slight but statistically insignificant increase. ALP and bilirubin levels remained unchanged at 72 U/L and 0.8 mg/dL, respectively. These results further support the notion that Natesto has a negligible impact on liver function over an extended period.

Liver Function at 24 Months

At the conclusion of the 24-month study, the mean ALT level was 31 U/L, AST was 23 U/L, ALP was 73 U/L, and bilirubin was 0.8 mg/dL. Although there was a gradual increase in ALT and AST levels, these values remained within the normal range and did not indicate any liver dysfunction. The consistency of ALP and bilirubin levels further corroborates the safety of Natesto regarding liver health.

Discussion and Implications

The findings of this study suggest that Natesto, when used over a 24-month period, does not significantly impact liver function in American males with hypogonadism. The slight increases in ALT and AST levels were within normal limits and did not indicate any pathological changes. These results are reassuring for clinicians and patients considering Natesto as a TRT option.

However, it is essential to continue monitoring liver function in patients on long-term TRT, as individual responses may vary. Additionally, further studies with larger cohorts and longer durations could provide more comprehensive insights into the safety profile of Natesto.

Conclusion

In conclusion, this 24-month biochemical analysis demonstrates that Natesto testosterone gel has a minimal impact on liver function in American males with hypogonadism. The stability of liver function markers over the study period supports the safety of Natesto as a TRT option. Clinicians can consider these findings when prescribing Natesto, while also emphasizing the importance of regular monitoring to ensure patient safety.